Traws Pharma (NASDAQ:TRAW) Issues Earnings Results, Beats Estimates By $0.03 EPS

Traws Pharma (NASDAQ:TRAW – Get Free Report) posted its earnings results on Monday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03, Zacks reports.

Traws Pharma Trading Down 10.3%

Shares of TRAW opened at $0.23 on Wednesday. Traws Pharma has a fifty-two week low of $0.22 and a fifty-two week high of $3.23. The stock has a fifty day moving average of $0.42 and a two-hundred day moving average of $1.05.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Traws Pharma in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, August 26th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $1.00.

Get Our Latest Report on Traws Pharma

About Traws Pharma

(Get Free Report)

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Featured Stories

Earnings History for Traws Pharma (NASDAQ:TRAW)

Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.